MUFG Securities EMEA plc Has $2.03 Million Holdings in Edwards Lifesciences Corporation $EW

MUFG Securities EMEA plc increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 111.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,790 shares of the medical research company’s stock after purchasing an additional 12,553 shares during the period. MUFG Securities EMEA plc’s holdings in Edwards Lifesciences were worth $2,028,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP bought a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $238,688,000. AQR Capital Management LLC raised its position in shares of Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after purchasing an additional 1,111,139 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Edwards Lifesciences by 1,952.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,149,700 shares of the medical research company’s stock worth $98,012,000 after buying an additional 1,093,692 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of several recent analyst reports. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Evercore reissued an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research report on Friday, April 24th. Finally, Wells Fargo & Company raised their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Edwards Lifesciences Trading Up 2.1%

Shares of Edwards Lifesciences stock opened at $88.33 on Tuesday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $89.14. The firm has a market capitalization of $50.86 billion, a PE ratio of 46.98, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company’s fifty day moving average price is $81.85 and its two-hundred day moving average price is $83.02.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the business earned $0.64 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 95,057 shares of company stock valued at $7,874,217. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.